Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
utidelone + capecitabine + oxaliplatin
- Development stage
- Phase 3
- Lead developer
- Beijing Biostar Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination consists of three chemotherapeutic agents: **utidelone** (a genetically engineered epothilone analogue with strong anti-tumor activity, particularly in tumors resistant to taxanes), **capecitabine** (an oral prodrug of 5-fluorouracil that interferes with DNA synthesis and repair), and **oxaliplatin** (a platinum-based agent that forms DNA crosslinks, disrupting DNA replication and transcription). Utidelone has been developed for metastatic breast cancer and shows synergistic activity with capecitabine. The triplet regimen is being investigated in phase II/III trials for first-line treatment of PD-L1-negative locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Each drug has a distinct mechanism of action, with the combination designed to address multiple pathways of tumor cell survival and proliferation[1][2][3].
- Other names
- utidelone capsule + capecitabine + oxaliplatin
02
Targets
DNATS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on utidelone + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on utidelone + capecitabine + oxaliplatin.